---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-001022"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T14:45:04.099075+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv reports FY2023 revenue $17.0M, net income $1.3M, declares special dividend $0.075/share

## Summary
- Revenue of $17.0M, down $2.4M YoY; net income of $1.3M, up $0.3M YoY.
- Gross profit margin improved 4.6 percentage points compared to last year.
- Special dividend of $0.075/share declared; payable Feb 15, 2024 to holders of record Jan 30, 2024.

## SEC filing metadata
- accession: 0001654954-24-001022
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495424001022/0001654954-24-001022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495424001022/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-001022
- JSON: https://secwatch.observer/filing/0001654954-24-001022.json
- Plain text: https://secwatch.observer/filing/0001654954-24-001022.txt

## Key facts
- Earnings Releases
  Pharma-Bio Serv, Inc. reported FY ended October 31, 2023 results: revenue approximately $17.0 million, net income approximately $1.3 million.
  - Period: FY ended October 31, 2023
  - Revenue: approximately $17.0 million
  - Net income: approximately $1.3 million
  - Result: reported results
  source text: Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2023 were approximately $17.0 million, a decrease of approximately $2.4 million when compared to last year. Additionally, net income for the year ended October 31, 2023 was approximately $1.3 million, an improvement of approximately $0.3 million when compared to last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1304161/000165495424001022/0001654954-24-001022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.